{
    "clinical_study": {
        "@rank": "126126", 
        "acronym": "OMEGA-PAD II", 
        "arm_group": [
            {
                "arm_group_label": "Pro-Omega", 
                "arm_group_type": "Experimental", 
                "description": "High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral\n      supplementation will improve systemic inflammation, vascular function, and symptomatic\n      status of patients with PAD. Investigators will explore novel mechanistic pathways by which\n      n-3 PUFA affect PAD, evaluating the role of specialized lipid mediators involved in the\n      resolution of inflammation."
        }, 
        "brief_title": "The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Disease", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The OMEGA-PAD II trial will be a 1:1 randomized, double-blinded trial comparing oral\n      supplementation of n-3 PUFA (4.4g/day) to placebo in claudicants (Rutherford stage 1-3) for\n      3 months. Eligible patients will be screened according to specified inclusion and exclusion\n      criteria. All patients will be treated per our current practice as reflected in the American\n      Heart Association Practice guidelines on PAD. Blood draws, vascular function testing and\n      6-minute walking tests will be performed at baseline and after 3 months. n-3 PUFA\n      supplementation will be achieved with 4 capsules of Pro-Omega twice daily (Nordic Naturals,\n      Watsonville, California, USA), corresponding to a total of 4.4g/day. Each ProOmega capsule\n      contains 325mg of EPA and 225mg of DHA. The placebo group will take the same number of\n      capsules containing inactive substance (soybean; Nordic Naturals), designed to be the same\n      color and shape as the treatment capsules."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Intermittent claudication (Rutherford 1-3)\n\n          2. Resting or exercise ankle-brachial index (ABI) <0.9\n\n          3. Age 50 and more\n\n        Exclusion Criteria:\n\n          1. Critical limb ischemia\n\n          2. Hypersensitivity/allergies to fish or seafood\n\n          3. Already on n-3 PUFA or equivalent\n\n          4. Significant renal, hepatic, and inflammatory disease\n\n          5. Concurrent severe infections\n\n          6. Acute illness (myocardial infarction, stroke, major surgery within 30 days)\n\n          7. Receiving immunosuppressive medications or steroids\n\n          8. Age < 50"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979874", 
            "org_study_id": "13-11778"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pro-Omega", 
                "description": "Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months", 
                "intervention_name": "Pro-Omega", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months", 
                "intervention_name": "ProOmega Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 22, 2014", 
        "link": {
            "description": "UCSF & SFVAMC Divisions of Vascular and Endovascular Surgery Clinical Trials", 
            "url": "http://vascular.surgery.ucsf.edu/research/clinical-research/clinical-trials.aspx"
        }, 
        "location": {
            "contact": {
                "email": "karen.chong@ucsfmedctr.org", 
                "last_name": "Karen Chong, BS", 
                "phone": "415-221-4810", 
                "phone_ext": "4708"
            }, 
            "contact_backup": {
                "email": "hugh.alley@ucsfmedctr.org", 
                "last_name": "Hugh Alley, BA", 
                "phone": "415-221-4810", 
                "phone_ext": "4708"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94121"
                }, 
                "name": "San Francisco Veterans Affairs Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Marlene S Grenon, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Christopher Owens, MD, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Warren Gasper, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Conte, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joseph Rapp, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation II", 
        "other_outcome": {
            "description": "Will improve walking distance during 6-minute walk test and improve parameters on the walking impairment questionnaire (WIQ).", 
            "measure": "Walking Performance", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "karen.chong@ucsfmedctr.org", 
            "last_name": "Karen Chong, BS", 
            "phone": "415-221-4810", 
            "phone_ext": "4708"
        }, 
        "overall_contact_backup": {
            "email": "hugh.alley@ucsfmedctr.org", 
            "last_name": "Hugh Alley, BA", 
            "phone": "415-221-4810", 
            "phone_ext": "4708"
        }, 
        "overall_official": {
            "affiliation": "UCSF & SFVAMC", 
            "last_name": "Marlene Grenon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "reduce circulating pro-inflammatory markers (PIMs) and increase pro-resolution mediators (PRMs) assayed using targeted metabolo-lipidomics, increase PRM production within peripheral circulating monocytes.", 
            "measure": "Systemic Inflammatory bio-markers", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "reference": [
            {
                "PMID": "22363018", 
                "citation": "Grenon SM, Hughes-Fulford M, Rapp J, Conte MS. Polyunsaturated fatty acids and peripheral artery disease. Vasc Med. 2012 Feb;17(1):51-63. doi: 10.1177/1358863X11429175. Review."
            }, 
            {
                "PMID": "22572621", 
                "citation": "Grenon SM, Aguado-Zuniga J, Hatton JP, Owens CD, Conte MS, Hughes-Fulford M. Effects of fatty acids on endothelial cells: inflammation and monocyte adhesion. J Surg Res. 2012 Sep;177(1):e35-43. doi: 10.1016/j.jss.2012.04.010. Epub 2012 Apr 27."
            }, 
            {
                "PMID": "23830313", 
                "citation": "Grenon SM, Conte MS, Nosova E, Alley H, Chong K, Harris WS, Vittinghoff E, Owens CD. Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. J Vasc Surg. 2013 Nov;58(5):1283-90. doi: 10.1016/j.jvs.2013.05.024. Epub 2013 Jul 2."
            }, 
            {
                "PMID": "24052491", 
                "citation": "Grenon SM, Owens CD, Alley H, Chong K, Yen PK, Harris W, Hughes-Fulford M, Conte MS. n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial. Vasc Med. 2013 Oct;18(5):263-74. doi: 10.1177/1358863X13503695. Epub 2013 Sep 19."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979874"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Will increase brachial artery flow-mediated vasodilation (FMD)and peripheral resistance (AiX) and decrease arterial stiffness in the lower extremities (PWV).", 
            "measure": "Endothelial Function", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}